Nuvation Bio Q1 Earnings Forecast Lowered by HC Wainwright

Key Points

• HC Wainwright lowered its Q1 2027 EPS forecast for Nuvation Bio to $0.00 from $0.01, while maintaining a Buy rating and a $21 price target.
• Nuvation Bio reported a quarterly loss of $0.12 per share, matching consensus, while revenue of $44.95 million exceeded estimates of $34.39 million.
• Shares fell 10% to $4.26 on Friday. RBC cut its price target to $17 from $20 but kept an Outperform rating; analysts’ consensus rating is Moderate Buy with a $12.89 target.

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Research analysts at HC Wainwright dropped their Q1 2027 earnings per share (EPS) estimates for Nuvation Bio in a report issued on Thursday, November 5th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their prior forecast of $0.01. HC Wainwright has a "Buy" rating and a $21.00 price objective on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.34) per share.

Nuvation Bio (NYSE:NUVB - Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $44.95 million during the quarter, compared to analyst estimates of $34.39 million. Nuvation Bio had a negative return on equity of 43.15% and a negative net margin of 67.38%.

Several other equities research analysts have also weighed in on the company. Royal Bank Of Canada dropped their target price on Nuvation Bio from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Thursday. Wedbush reissued an "outperform" rating and set a $11.00 price target on shares of Nuvation Bio in a report on Wednesday, September 16th. Wall Street Zen lowered shares of Nuvation Bio from a "hold" rating to a "sell" rating in a research report on Saturday, October 10th. Cantor Fitzgerald initiated coverage on shares of Nuvation Bio in a report on Friday, August 21st. They issued an "overweight" rating on the stock. Finally, B. Riley Financial reaffirmed a "buy" rating on shares of Nuvation Bio in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.89.

Nuvation Bio Trading Down 10.0%

NYSE:NUVB opened at $4.26 on Friday. Nuvation Bio has a 12-month low of $4.05 and a 12-month high of $9.75. The firm has a market capitalization of $1.49 billion, a P/E ratio of -10.64 and a beta of 1.73. The company has a debt-to-equity ratio of 0.96, a current ratio of 8.37 and a quick ratio of 8.14. The business has a 50 day simple moving average of $5.44 and a 200 day simple moving average of $5.38.

Insider Transactions at Nuvation Bio

In related news, insider Gary Hattersley sold 100,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total value of $709,000.00. Following the sale, the insider directly owned 100,000 shares in the company, valued at $709,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 30.11% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership lifted its stake in shares of Nuvation Bio by 75.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,439,357 shares of the company's stock worth $6,175,000 after acquiring an additional 619,725 shares during the period. NewEdge Advisors LLC increased its stake in shares of Nuvation Bio by 19.5% during the second quarter. NewEdge Advisors LLC now owns 1,231,733 shares of the company's stock valued at $6,996,000 after acquiring an additional 200,621 shares during the period. Tanaka Capital Management Inc. increased its stake in shares of Nuvation Bio by 7.2% during the first quarter. Tanaka Capital Management Inc. now owns 901,825 shares of the company's stock valued at $3,869,000 after acquiring an additional 60,220 shares during the period. Wellington Management Group LLP raised its holdings in Nuvation Bio by 6.5% during the second quarter. Wellington Management Group LLP now owns 715,781 shares of the company's stock worth $4,066,000 after purchasing an additional 43,637 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Nuvation Bio during the second quarter worth approximately $3,804,000. Institutional investors and hedge funds own 61.67% of the company's stock.

Nuvation Bio News Summary

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: IBTROZI generated $27.5 million in Q3 net product revenue, and the company reported $45.0 million in total revenue, ahead of the cited $34.39 million analyst estimate. Management said IBTROZI grew 18% sequentially and leads the ROS1 market in new patient starts and active patients. Nuvation Bio Q3 results and business update
• Positive Sentiment: The company outlined potential European approval for IBTROZI in the first half of next year, which could trigger an approximately $30 million milestone payment. Europe approval and milestone update
• Positive Sentiment: Further pipeline and product catalysts include an FDA label update reflecting a 49.7-month median duration of response for IBTROZI in the specified patient group, Fast Track designation for safusidenib, and $663.4 million in cash, equivalents, and marketable securities at quarter-end. Nuvation Bio Q3 results and business update
• Negative Sentiment: Royal Bank of Canada lowered its price target from $20 to $17, while maintaining an Outperform rating. B. Riley also cut its target, from $14 to $13, but kept its Buy rating. Target reductions may weigh on sentiment even though both firms remain positive on the shares. Royal Bank of Canada rating update B. Riley price target update
• Negative Sentiment: NUVB reported a Q3 loss of $0.12 per share. That matched the consensus cited by some reports but was a penny worse than the $0.11 loss estimate cited by Zacks, making the earnings picture slightly mixed despite the revenue beat. Zacks Q3 earnings report

Nuvation Bio Company Profile

Nuvation Bio, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with cancer. The company seeks to address areas of significant unmet need, with an emphasis on targeted therapies for solid tumors.

Nuvation Bio's lead product is taletrectinib, a next-generation tyrosine kinase inhibitor designed for patients with ROS1-positive non-small cell lung cancer (NSCLC), including certain tumors that have developed resistance to earlier ROS1-targeted treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.